Ono Pharmaceutical (OTCMKTS:OPHLF) vs. Ovid Therapeutics (NASDAQ:OVID) Head to Head Comparison

Ovid Therapeutics (NASDAQ:OVID) and Ono Pharmaceutical (OTCMKTS:OPHLF) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ovid Therapeutics and Ono Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.38%	-20.76%
Ono Pharmaceutical	15.04%	9.41%	7.39%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Ovid Therapeutics and Ono Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1	0	11	1	2.92
Ono Pharmaceutical	0	1	0	0	2.00

Ovid Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 143.41%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Ono Pharmaceutical.

Volatility & Risk

Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.

Earnings & Valuation

This table compares Ovid Therapeutics and Ono Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25 million	64.17	-$17.41 million	($0.31)	-7.95
Ono Pharmaceutical	$3.43 billion	2.04	$436.04 million	$1.01	14.75

Ono Pharmaceutical has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Ono Pharmaceutical beats Ovid Therapeutics on 8 of the 15 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Founded in 1717 as a medicine wholesaler, the company is headquartered in Osaka. Ono’s research and product portfolio spans areas including oncology, immunology, neurology and diabetes. A notable product is Opdivo (nivolumab), an immuno-oncology medicine developed through a collaboration involving Ono and Medarex, which was later acquired by Bristol Myers Squibb.